TY - JOUR
T1 - Immunotherapy for the management of advanced melanoma
T2 - The next steps
AU - Zikich, Dragoslav
AU - Schachter, Jacob
AU - Besser, Michal J.
PY - 2013/8
Y1 - 2013/8
N2 - Melanoma is an immunogenic tumor that can induce a natural immune response. A number of immunotherapy-based approaches have been developed over the past decades, and certain degrees of effectiveness were achieved by the use of cytokines, adoptive cell transfer and T-cell immune modulators. Currently, interleukin-2 and the immune stimulatory antibody, ipilimumab, are the only two approved immunotherapies for metastatic melanoma, but various new therapies are in promising developmental stages. This comprehensive review will discuss the latest achievements of immunotherapy and emerging directions for the management of advanced melanoma.
AB - Melanoma is an immunogenic tumor that can induce a natural immune response. A number of immunotherapy-based approaches have been developed over the past decades, and certain degrees of effectiveness were achieved by the use of cytokines, adoptive cell transfer and T-cell immune modulators. Currently, interleukin-2 and the immune stimulatory antibody, ipilimumab, are the only two approved immunotherapies for metastatic melanoma, but various new therapies are in promising developmental stages. This comprehensive review will discuss the latest achievements of immunotherapy and emerging directions for the management of advanced melanoma.
UR - http://www.scopus.com/inward/record.url?scp=84880896759&partnerID=8YFLogxK
U2 - 10.1007/s40257-013-0013-0
DO - 10.1007/s40257-013-0013-0
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 23516145
AN - SCOPUS:84880896759
SN - 1175-0561
VL - 14
SP - 261
EP - 272
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
IS - 4
ER -
